Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on SPRY stock, giving a Buy rating yesterday.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight ARS Pharmaceuticals’ strategic positioning and growth potential. The recent expansion of their partnership with ALK Abelló A/S is seen as a significant positive, as it enhances the commercial resources and salesforce infrastructure for the US launch of neffy, a treatment for Type 1 allergy and anaphylaxis. This collaboration is expected to effectively target pediatricians, thereby maximizing neffy’s market penetration and leveraging its first-mover advantage, especially during the peak back-to-school season when epinephrine prescriptions typically increase.
Moreover, ARS Pharmaceuticals has been proactive in securing broader and more favorable insurance coverage, which is anticipated to reduce authorization hurdles and facilitate wider access to neffy. The company’s management has also planned a direct-to-consumer campaign to coincide with the product’s availability for a significant segment of the pediatric population. These strategic initiatives, combined with the expected increase in salesforce reach and cost synergies from the partnership with ALK, underpin the positive outlook for ARS Pharmaceuticals and justify the Buy rating.
According to TipRanks, Ruiz is an analyst with an average return of -12.6% and a 33.94% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and United Therapeutics.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $30.00 price target.